BIOMAT Database Logo BIOMAT Database Logo

Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease. 2006

Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Department of Pediatrics, Iwate Medical University School of Medicine, Morioka, Japan.

A 3-year-old boy with Kawasaki disease developed a cerebral infarction after high-dose intravenous immunoglobulin. Aspirin did not prevent the stroke. Based on the numerous reports of thrombosis due to high-dose immunoglobulin in older individuals, we conclude that it is necessary to be aware of this complication when treating children with Kawasaki disease.

UI MeSH Term Description Entries
D008297 Male Males
D009080 Mucocutaneous Lymph Node Syndrome An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities. Kawasaki Disease,Lymph Node Syndrome, Mucocutaneous,Kawasaki Syndrome
D002544 Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). Anterior Choroidal Artery Infarction,Cerebral Infarct,Infarction, Cerebral,Posterior Choroidal Artery Infarction,Subcortical Infarction,Cerebral Infarction, Left Hemisphere,Cerebral Infarction, Right Hemisphere,Cerebral, Left Hemisphere, Infarction,Cerebral, Right Hemisphere, Infarction,Infarction, Cerebral, Left Hemisphere,Infarction, Cerebral, Right Hemisphere,Infarction, Left Hemisphere, Cerebral,Infarction, Right Hemisphere, Cerebral,Left Hemisphere, Cerebral Infarction,Left Hemisphere, Infarction, Cerebral,Right Hemisphere, Cerebral Infarction,Right Hemisphere, Infarction, Cerebral,Cerebral Infarctions,Cerebral Infarcts,Infarct, Cerebral,Infarction, Subcortical,Infarctions, Cerebral,Infarctions, Subcortical,Infarcts, Cerebral,Subcortical Infarctions
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I

Related Publications

Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Single high-dose intravenous immunoglobulin therapy for kawasaki disease increases plasma viscosity.
August 2005, Circulation journal : official journal of the Japanese Circulation Society,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
October 2008, Yonsei medical journal,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
[Acute renal insufficiency and cerebral infarction during high-dose intravenous immunoglobulin therapy].
December 1998, La Revue de medecine interne,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki disease.
January 2002, Acta paediatrica (Oslo, Norway : 1992),
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Recommendations for intravenous immunoglobulin therapy of Kawasaki disease.
November 1992, The Pediatric infectious disease journal,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
High-dose intravenous gammaglobulin for Kawasaki disease.
November 1984, Lancet (London, England),
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
High-dose intravenous gammaglobulin for Kawasaki disease.
December 1983, Lancet (London, England),
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease.
January 1995, The Journal of international medical research,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
High-dose intravenous gamma-globulin therapy in Kawasaki disease.
January 1989, Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui,
Yasunori Wada, and Atsushi Kamei, and Yukiharu Fujii, and Ken Ishikawa, and Shoichi Chida
Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
January 2014, International archives of allergy and immunology,
Copied contents to your clipboard!